Denali Therapeutics INC Form 4 insider transactions

Director Marc Tessier-Lavigne reports acquisition of stock and option awards in Denali Therapeutics.

Director Vicki L Sato reports acquisition of Denali Therapeutics shares and stock options.

Director Jennifer E. Cook reported acquiring shares and stock options in Denali Therapeutics Inc. on May 31, 2024.

Director David P. Schenkein reports acquisition of restricted stock units and stock options in Denali Therapeutics.

Director Jay T. Flatley reports acquisition of Denali Therapeutics shares through Restricted Stock Units (RSUs) and stock options.

Director Erik Harris reports acquisition of stock options and restricted stock units in Denali Therapeutics.

Director Peter Klein reported the acquisition of stock and stock options in Denali Therapeutics on May 31, 2024.

Director Vicki L. Sato sold 1,674 shares of Denali Therapeutics Inc. (DNLI) common stock at a price of $20.39 per share on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics Inc. (DNLI) common stock at a price of $18.29 per share on April 15, 2024, under a pre-arranged 10b5-1 trading plan.

Steve E. Krognes, a director at Denali Therapeutics Inc., sold 92,500 shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics' CEO, Ryan J. Watts, made an in-kind charitable contribution of 40,000 shares of DNLI stock to a donor-advised fund on March 29, 2024.

Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics Inc. (DNLI) common stock at an average price of $20.10, executed under a pre-arranged 10b5-1 trading plan.